Impact of colistin-initiation delay on mortality of ventilator-associated pneumonia caused by A. baumannii
Open Access
- 31 October 2016
- journal article
- research article
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 10 (10) , 1129-1134
Abstract
Introduction: There has been increased incidence and high mortality in cases with ventilator-associated pneumonia (VAP) caused by colistin-only-susceptible Acinetobacter baumannii (COS-AB). Colistin has emerged as a therapeutic option for VAP caused by multidrug-resistant Gram-negative organisms including COS-AB. A retrospective study was conducted to examine the impact of early versus late initiation of colistin on 30-day mortality of critically ill patients with VAP caused by COS-AB. Methodology: Critically ill patients with VAP caused by COS-AB who received colistin were enrolled. The receiver operating characteristic (ROC) curve was used to identify the temporal breakpoint that maximized the difference in 30-day mortality. Results: A total of 56 patients (34 men and 22 women) were included in the study. About 86% of all cases were late-onset VAP. The 30-day mortality was 46.4%. The rate was higher among patients with admission Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 18 and patients with a delay of more than four days in initiating colistin treatment. The mortality rate was 26.9% among patients with treatment delay of four or fewer days and 63.3% for patients with a treatment delay of more than four days. Conclusions: A delay of four days or more in initiating colistin in patients with VAP caused by COS-AB significantly increases mortality. Colistin should be considered in the empirical protocols in late-onset VAP cases when COS-AB is highly suspected.Keywords
This publication has 23 references indexed in Scilit:
- Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumoniaInternational Journal of Antimicrobial Agents, 2014
- Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilator-associated pneumonia in an adult intensive care unit in Saudi ArabiaInternational Journal of Infectious Diseases, 2013
- Impact of the initiation time of colistin treatment for Acinetobacter infectionsJournal of Infection and Chemotherapy, 2013
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patientsInternational Journal of Antimicrobial Agents, 2010
- Clinical characteristics and risk factors of colistin-induced nephrotoxicityInternational Journal of Antimicrobial Agents, 2009
- Nephrotoxicity of intravenous colistin: a prospective evaluationInternational Journal of Antimicrobial Agents, 2005
- Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort studyIntensive Care Medicine, 2005
- Treatment of Multidrug‐ResistantAcinetobacter baumanniiVentilator‐Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem‐Susceptible VAPClinical Infectious Diseases, 2003
- Endemic Carbapenem-Resistant Acinetobacter Species in Brooklyn, New York: Citywide Prevalence, Interinstitutional Spread, and Relation to Antibiotic UsageClinical Infectious Diseases, 2000
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999